Forte Biosciences, Inc. (FBRX) |
| 54.78 -4.92 (-8.24%) 07-24 16:00 |
| Open: | 59.28 |
| High: | 60.4 |
| Low: | 54.64 |
| Volume: | 568,928 |
| Market Cap: | 1,122(M) |
| PE Ratio: | -11.81 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 72.95 |
| Resistance 1: | 62.46 |
| Pivot price: | 42.57 |
| Support 1: | 34.30 |
| Support 2: | 16.89 |
| 52w High: | 62.46 |
| 52w Low: | 9.1 |
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Financials
| EPS | -4.580 |
| Book Value | 2.360 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -83.9 |
| Return on Equity (ttm) | -188.4 |
Company news
Sun, 26 Jul 2026
TradingKey - TradingKey
Fri, 24 Jul 2026
Forte Biosciences, Inc. Revenue Breakdown – NASDAQ:FBRX - TradingView
Thu, 23 Jul 2026
Forte Biosciences (FBRX) Is Up 17.4% After Positive Phase 1b FB102 Vitiligo Data Release - Sahm
Wed, 22 Jul 2026
Forte Biosciences stock hits 52-week high at 52.75 USD - Investing.com
Sun, 19 Jul 2026
Is Forte Biosciences (FBRX) Fully Valued Following Its Positive FB102 Vitiligo Data? - simplywall.st
Thu, 16 Jul 2026
Millennium reports 3.2% Forte Biosciences (FBRX) stake in ownership filing - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
